Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.5Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -0.62%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with significant revenue growth, strategic partnerships, and a strong cash position outweighing the increased operating expenses.Company Guidance
During the first quarter of 2025, Zymeworks reported a net loss of $22.6 million, a decrease from $31.7 million in the same period of 2024, due to an increase in revenue to $27.1 million from $10 million, partly driven by milestone revenues from GSK and Daiichi Sankyo. Operating expenses rose by 10% to $52.7 million, mainly from increased R&D expenses, while cash resources slightly decreased to $321.6 million. The company anticipates its cash, combined with expected regulatory milestones, to fund operations into the second half of 2027. Key developments included six poster presentations at AACR, highlighting progress in their antibody drug conjugate and T-cell engager pipeline, and anticipated presentations at upcoming medical conferences. The potential approval of zanidatamab by the EMA could lead to increased royalty revenue, while collaborations like the one with JNJ could yield substantial future financial benefits.Significant Revenue Growth
Zymeworks reported a revenue increase to $27.1 million for Q1 2025, up from $10 million in the same period in 2024, largely driven by milestone revenues from partnerships with GSK and Daiichi Sankyo.
Positive Opinion from EMA
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for the approval of zanidatamab for advanced HER2+ biliary tract cancer, which could increase royalty revenues for Zymeworks.
Strong Pipeline and Partnerships
Zymeworks presented six posters at the AACR Annual Meeting, showcasing its progress in antibody drug conjugates and T-cell engagers. Notable partnerships with Jazz and JNJ highlight ongoing and future developments.
Reduction in Net Loss
Net loss decreased to $22.6 million for Q1 2025 from $31.7 million in Q1 2024, attributed to increased revenue.
Robust Cash Position
Zymeworks had $321.6 million in cash resources as of March 31, 2025, expected to fund operations into the second half of 2027.
---
ZYME Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZYME Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $11.32 | $11.30 | -0.18% |
Mar 05, 2025 | $13.18 | $12.13 | -7.97% |
Oct 31, 2024 | $13.70 | $13.28 | -3.07% |
Aug 01, 2024 | $10.11 | $10.20 | +0.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zymeworks Inc (ZYME) report earnings?
Zymeworks Inc (ZYME) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Zymeworks Inc (ZYME) earnings time?
Zymeworks Inc (ZYME) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYME EPS forecast?
ZYME EPS forecast for the fiscal quarter 2025 (Q2) is -0.5.
---